Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells

Frontiers in Bioscience - Elite

Volumn 3 E, Issue 2, 2011, Pages 515-528

  Srivastava, Rakesh K ^a   Tang, Su Ni ^a   Zhu, Wenyu ^a   Meeker, Daniel ^a   Shankar, Sharmila ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Nanog; Pancreatic cancer; Quercetin; Stem cells; Sulforaphane

Indexed keywords

BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CASPASE 3; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN BCL 2; QUERCETIN; SHORT HAIRPIN RNA; SULFORAPHANE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR ZEB1; VIMENTIN; HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN; SULFORAFAN; THIOCYANIC ACID DERIVATIVE; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL CYCLE ARREST; CELL RENEWAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DIETARY INTAKE; DRUG POTENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PROTEIN PHOSPHORYLATION; TUMOR RECURRENCE; TUMOR SPHEROID; ANALYSIS OF VARIANCE; DRUG ANTAGONISM; DRUG EFFECT; GENE VECTOR; GENETICS; LENTIVIRINAE; METABOLISM; PANCREAS TUMOR; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG SYNERGISM; GENETIC VECTORS; HOMEODOMAIN PROTEINS; HUMANS; LENTIVIRUS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUERCETIN; THIOCYANATES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 79957794952     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e266     Document Type: Article

References (119)

1. A. L. Warshaw and C. Fernandez-del Castillo: Pancreatic carcinoma. N Engl J Med, 326(7), 455-65 (1992)
2. C. J. Magee, P. Ghaneh and J. P. Neoptolemos: Surgical and medical therapy for pancreatic carcinoma. Best Pract Res Clin Gastroenterol, 16(3), 435-55 (2002)
3. T. P. Yeo, R. H. Hruban, S. D. Leach, R. E. Wilentz, T. A. Sohn, S. E. Kern, C. A. Iacobuzio-Donahue, A. Maitra, M. Goggins, M. I. Canto, R. A. Abrams, D. Laheru, E. M. Jaffee, M. Hidalgo and C. J. Yeo: Pancreatic cancer. Curr Probl Cancer, 26(4), 176-275 (2002)
4. R. J. Jones, W. H. Matsui and B. D. Smith: Cancer stem cells: are we missing the target? J Natl Cancer Inst, 96(8), 583-5 (2004) (Pubitemid 38584981)
5. T. Reya, S. J. Morrison, M. F. Clarke and I. L. Weissman: Stem cells, cancer, and cancer stem cells. Nature, 414(6859), 105-11 (2001) (Pubitemid 33041634)
6. F. Bednar and D. M. Simeone: Pancreatic cancer stem cells and relevance to cancer treatments. J Cell Biochem, 107(1), 40-5 (2009)
7. I. Ischenko, H. Seeliger, A. Kleespies, M. K. Angele, M. E. Eichhorn, K. W. Jauch and C. J. Bruns: Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg, 395(1), 1-10 (2010)
8. C. J. Lee, J. Dosch and D. M. Simeone: Pancreatic cancer stem cells. J Clin Oncol, 26(17), 2806-12 (2008)
9. C. Li, D. G. Heidt, P. Dalerba, C. F. Burant, L. Zhang, V. Adsay, M. Wicha, M. F. Clarke and D. M. Simeone: Identification of pancreatic cancer stem cells. Cancer Res, 67(3), 1030-7 (2007)
10. C. Li, C. J. Lee and D. M. Simeone: Identification of human pancreatic cancer stem cells. Methods Mol Biol, 568, 161-73 (2009)
11. M. T. Mueller, P. C. Hermann and C. Heeschen: Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci (Elite Ed), 2, 602-13 (2010)
12. D. M. Simeone: Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res, 14(18), 5646-8 (2008)
13. H. Korkaya, A. Paulson, E. Charafe-Jauffret, C. Ginestier, M. Brown, J. Dutcher, S. G. Clouthier and M. S. Wicha: Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol, 7(6), e1000121 (2009)
14. D. Hambardzumyan, M. Squatrito and E. C. Holland: Radiation resistance and stem-like cells in brain tumors. Cancer Cell, 10(6), 454-6 (2006) (Pubitemid 44854752)
15. N. Shafee, C. R. Smith, S. Wei, Y. Kim, G. B. Mills, G. N. Hortobagyi, E. J. Stanbridge and E. Y. Lee: Cancer stem cells contribute to cisplatin resistance in Brca1/p53- mediated mouse mammary tumors. Cancer Res, 68(9), 3243-50 (2008)
16. R. J. Jones: Cancer stem cells-clinical relevance. J Mol Med, 87(11), 1105-10 (2009)
17. S. K. Singh, I. D. Clarke, M. Terasaki, V. E. Bonn, C. Hawkins, J. Squire and P. B. Dirks: Identification of a cancer stem cell in human brain tumors. Cancer Res, 63(18), 5821-8 (2003) (Pubitemid 37187480)
18. S. K. Singh, C. Hawkins, I. D. Clarke, J. A. Squire, J. Bayani, T. Hide, R. M. Henkelman, M. D. Cusimano and P. B. Dirks: Identification of human brain tumour initiating cells. Nature, 432(7015), 396-401 (2004) (Pubitemid 39551674)
19. H. D. Hemmati, I. Nakano, J. A. Lazareff, M. Masterman-Smith, D. H. Geschwind, M. Bronner-Fraser and H. I. Kornblum: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A, 100(25), 15178-83 (2003) (Pubitemid 37518036)
20. C. A. O'Brien, A. Pollett, S. Gallinger and J. E. Dick: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445(7123), 106-10 (2007) (Pubitemid 46067310)
21. L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle and R. De Maria: Identification and expansion of human colon-cancer-initiating cells. Nature, 445(7123), 111-5 (2007) (Pubitemid 46067311)
22. L. Ricci-Vitiani, A. Pagliuca, E. Palio, A. Zeuner and R. De Maria: Colon cancer stem cells. Gut, 57(4), 538-48 (2008) (Pubitemid 351442540)
23. S. Yin, J. Li, C. Hu, X. Chen, M. Yao, M. Yan, G. Jiang, C. Ge, H. Xie, D. Wan, S. Yang, S. Zheng and J. Gu: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer, 120(7), 1444-50 (2007) (Pubitemid 46355378)
24. S. Ma, K. W. Chan, L. Hu, T. K. Lee, J. Y. Wo, I. O. Ng, B. J. Zheng and X. Y. Guan: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology, 132(7), 2542-56 (2007) (Pubitemid 46890873)
25. R. Birnie, S. D. Bryce, C. Roome, V. Dussupt, A. Droop, S. H. Lang, P. A. Berry, C. F. Hyde, J. L. Lewis, M. J. Stower, N. J. Maitland and A. T. Collins: Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol, 9(5), R83 (2008)
26. C. L. Eaton, M. Colombel, G. van der Pluijm, M. Cecchini, A. Wetterwald, J. Lippitt, I. Rehman, F. Hamdy and G. Thalman: Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate, 70(8), 875-82 (2010)
27. N. J. Maitland, S. D. Bryce, M. J. Stower and A. T. Collins: Prostate cancer stem cells: a target for new therapies. Ernst Schering Found Symp Proc(5), 155-79 (2006)
28. M. Trerotola, S. Rathore, H. L. Goel, J. Li, S. Alberti, M. Piantelli, D. Adams, Z. Jiang and L. R. Languino: CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am J Transl Res, 2(2), 135-44 (2010)
29. P. C. Hermann, S. L. Huber, T. Herrler, A. Aicher, J. W. Ellwart, M. Guba, C. J. Bruns and C. Heeschen: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1(3), 313-23 (2007) (Pubitemid 47355323)
30. K. Quint, S. Stintzing, B. Alinger, C. Hauser-Kronberger, O. Dietze, S. Gahr, E. G. Hahn, M. Ocker and D. Neureiter: The expression pattern of PDX-1, SHH, Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer. Pancreatology, 9(1-2), 116-26 (2009)
31. Y. Katoh and M. Katoh: Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). Int J Mol Med, 18(6), 1019-23 (2006)
32. S. K. Roy, R. K. Srivastava and S. Shankar: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal, 5(1), 10 (2010)
33. B. Hutzen, W. Willis, S. Jones, L. Cen, S. Deangelis, B. Fuh and J. Lin: Dietary agent, benzyl isothiocyanate inhibits signal transducer and activator of transcription 3 phosphorylation and collaborates with sulforaphane in the growth suppression of PANC-1 cancer cells. Cancer Cell Int, 9, 24 (2009)
34. G. Kallifatidis, V. Rausch, B. Baumann, A. Apel, B. M. Beckermann, A. Groth, J. Mattern, Z. Li, A. Kolb, G. Moldenhauer, P. Altevogt, T. Wirth, J. Werner, P. Schemmer, M. W. Buchler, A. V. Salnikov and I. Herr: Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut, 58(7), 949-63 (2009)
35. J. W. Lampe: Sulforaphane: from chemoprevention to pancreatic cancer treatment? Gut, 58(7), 900-2 (2009)
36. N. A. Pham, J. W. Jacobberger, A. D. Schimmer, P. Cao, M. Gronda and D. W. Hedley: The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther, 3(10), 1239-48 (2004) (Pubitemid 39440169)
37. Y. Li, T. Zhang, H. Korkaya, S. Liu, H. F. Lee, B. Newman, Y. Yu, S. G. Clouthier, S. J. Schwartz, M. S. Wicha and D. Sun: Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells. Clin Cancer Res,16(9), 2580-90 (2010)
38. S. Shankar, S. Ganapathy and R. K. Srivastava: Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res, 14(21), 6855-66 (2008)
39. S. Batra, R. P. Sahu, P. K. Kandala and S. K. Srivastava: Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. Mol Cancer Ther, 9(6), 1596-608 (2010)
40. A. Basu and S. Haldar: Anti-proliferative and proapoptotic effects of benzyl isothiocyanate on human pancreatic cancer cells is linked to death receptor activation and RasGAP/Rac1 down-modulation. Int J Oncol, 35(3), 593-9 (2009)
41. S. K. Srivastava and S. V. Singh: Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis, 25(9), 1701-9 (2004) (Pubitemid 39214313)
42. S. Cauchi, W. Han, S. V. Kumar and S. D. Spivack: Haplotype-environment interactions that regulate the human glutathione S-transferase P1 promoter. Cancer Res, 66(12), 6439-48 (2006)
43. R. Davis, K. P. Singh, R. Kurzrock and S. Shankar: Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep, 22(6), 1473-8 (2009)
44. M. G. Hertog, E. J. Feskens, P. C. Hollman, M. B. Katan and D. Kromhout: Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet, 342(8878), 1007-11 (1993) (Pubitemid 23314801)
45. M. G. Hertog, D. Kromhout, C. Aravanis, H. Blackburn, R. Buzina, F. Fidanza, S. Giampaoli, A. Jansen, A. Menotti, S. Nedeljkovic and et al.: Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med, 155(4), 381-6 (1995)
46. P. Knekt, R. Jarvinen, R. Seppanen, M. Hellovaara, L. Teppo, E. Pukkala and A. Aromaa: Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol, 146(3), 223-30 (1997) (Pubitemid 27329723)
47. S. J. Lee, Y. S. Jung, S. H. Lee, H. Y. Chung and B. J. Park: Isolation of a chemical inhibitor against K-Ras-induced p53 suppression through natural compound screening. Int J Oncol, 34(6), 1637-43 (2009)
48. L. Zhang, E. Angst, J. L. Park, A. Moro, D. W. Dawson, H. A. Reber, G. Eibl, O. J. Hines, V. L. Go and Q. Y. Lu: Quercetin aglycone is bioavailable in murine pancreas and pancreatic xenografts. J Agric Food Chem, 58(12), 7252-7 (2010)
49. W. Zhou, G. Kallifatidis, B. Baumann, V. Rausch, J. Mattern, J. Gladkich, N. Giese, G. Moldenhauer, T. Wirth, M. W. Buchler, A. V. Salnikov and I. Herr: Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol, 37(3), 551-61 (2010)
50. J. Duraj, K. Zazrivcova, J. Bodo, M. Sulikova and J. Sedlak: Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma, 52(4), 273-9 (2005) (Pubitemid 41076192)
51. S. Kothan, S. Dechsupa, G. Leger, J. L. Moretti, J. Vergote and S. Mankhetkorn: Spontaneous mitochondrial membrane potential change during apoptotic induction by quercetin in K562 and K562/adr cells. Can J Physiol Pharmacol, 82(12), 1084-90 (2004) (Pubitemid 40343645)
52. T. Efferth, M. Davey, A. Olbrich, G. Rucker, E. Gebhart and R. Davey: Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis, 28(2), 160-8 (2002) (Pubitemid 34743750)
53. P. Limtrakul, O. Khantamat and K. Pintha: Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother, 17(1), 86-95 (2005) (Pubitemid 40463763)
54. C. L. Shapiro, L. Ayash, I. J. Webb, R. Gelman, J. Keating, L. Williams, G. Demetri, P. Clark, A. Elias, D. Duggan, D. Hayes, D. Hurd and I. C. Henderson: Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol, 15(2), 674-83 (1997) (Pubitemid 27075135)
55. E. M. Leslie, Q. Mao, C. J. Oleschuk, R. G. Deeley and S. P. Cole: Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol Pharmacol, 59(5), 1171-80 (2001) (Pubitemid 32381597)
56. S. Y. Chung, M. K. Sung, N. H. Kim, J. O. Jang, E. J. Go and H. J. Lee: Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res, 28(7), 823-8 (2005)
57. J. J. van Zanden, H. van der Woude, J. Vaessen, M. Usta, H. M. Wortelboer, N. H. Cnubben and I. M. Rietjens: The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochem Pharmacol, 74(2), 345-51 (2007) (Pubitemid 46890811)
58. N. Galili, R. J. Davis, W. J. Fredericks, S. Mukhopadhyay, F. J. Rauscher, 3rd, B. S. Emanuel, G. Rovera and F. G. Barr: Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet, 5(3), 230-5 (1993) (Pubitemid 23330384)
59. E. Anderson, R. B. Clarke and A. Howell: Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia, 3(1), 23-35 (1998) (Pubitemid 128513217)
60. J. Hillion, M. Le Coniat, P. Jonveaux, R. Berger and O. A. Bernard: AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood, 90(9), 3714-9 (1997) (Pubitemid 27473443)
61. A. Borkhardt, R. Repp, O. A. Haas, T. Leis, J. Harbott, J. Kreuder, J. Hammermann, T. Henn and F. Lampert: Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene, 14(2), 195-202 (1997) (Pubitemid 27068305)
62. L. P. Van Der Heide, M. F. Hoekman and M. P. Smidt: The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J, 380(Pt 2), 297-309 (2004) (Pubitemid 38788101)
63. A. Brunet, A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis and M. E. Greenberg: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96(6), 857-68 (1999) (Pubitemid 29165088)
64. S. Guo, G. Rena, S. Cichy, X. He, P. Cohen and T. Unterman: Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J Biol Chem, 274(24), 17184-92 (1999)
65. R. H. Medema, G. J. Kops, J. L. Bos and B. M. Burgering: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature, 404(6779), 782-7 (2000) (Pubitemid 30212408)
66. N. Nakamura, S. Ramaswamy, F. Vazquez, S. Signoretti, M. Loda and W. R. Sellers: Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol, 20(23), 8969-82 (2000) (Pubitemid 32245927)
67. P. F. Dijkers, R. H. Medema, C. Pals, L. Banerji, N. S. Thomas, E. W. Lam, B. M. Burgering, J. A. Raaijmakers, J. W. Lammers, L. Koenderman and P. J. Coffer: Forkhead transcription factor FKHR-L1 modulates cytokine dependent transcriptional regulation of p27(KIP1). Mol Cell Biol, 20(24), 9138-48 (2000) (Pubitemid 32246103)
68. P. F. Dijkers, K. U. Birkenkamp, E. W. Lam, N. S. Thomas, J. W. Lammers, L. Koenderman and P. J. Coffer: FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol, 156(3), 531-42 (2002) (Pubitemid 34839900)
69. A. Cappellini, G. Tabellini, M. Zweyer, R. Bortul, P. L. Tazzari, A. M. Billi, F. Fala, L. Cocco and A. M. Martelli: The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression. Leukemia, 17(11), 2157-67 (2003) (Pubitemid 37428381)
70. B. M. Burgering and G. J. Kops: Cell cycle and death control: long live Forkheads. Trends Biochem Sci, 27(7), 352-60 (2002) (Pubitemid 34756518)
71. P. F. Dijkers, R. H. Medema, J. W. Lammers, L. Koenderman and P. J. Coffer: Expression of the proapoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol, 10(19), 1201-4 (2000)
72. J. Gilley, P. J. Coffer and J. Ham: FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol, 162(4), 613-22 (2003) (Pubitemid 37022939)
73. T. T. Tang, D. Dowbenko, A. Jackson, L. Toney, D. A. Lewin, A. L. Dent and L. A. Lasky: The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem, 277(16), 14255-65 (2002) (Pubitemid 34968040)
74. R. A. Perugini, T. P. McDade, F. J. Vittimberga, Jr. and M. P. Callery: Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res, 90(1), 39-44 (2000) (Pubitemid 30317175)
75. S. A. Shah, M. W. Potter, M. H. Hedeshian, R. D. Kim, R. S. Chari and M. P. Callery: PI-3' kinase and NF-kappaB cross-signaling in human pancreatic cancer cells. J Gastrointest Surg, 5(6), 603-12; discussion 612-3 (2001)
76. V. M. Bondar, B. Sweeney-Gotsch, M. Andreeff, G. B. Mills and D. J. McConkey: Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther, 1(12), 989-97 (2002)
77. J. Q. Cheng, B. Ruggeri, W. M. Klein, G. Sonoda, D. A. Altomare, D. K. Watson and J. R. Testa: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A, 93(8), 3636-41 (1996) (Pubitemid 26127592)
78. B. A. Ruggeri, L. Huang, M. Wood, J. Q. Cheng and J. R. Testa: Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog, 21(2), 81-6 (1998) (Pubitemid 28122842)
79. D. A. Altomare, S. Tanno, A. De Rienzo, A. J. Klein-Szanto, S. Tanno, K. L. Skele, J. P. Hoffman and J. R. Testa: Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem, 88(1), 470-6 (2003)
80. M. G. Schlieman, B. N. Fahy, R. Ramsamooj, L. Beckett and R. J. Bold: Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer, 89(11), 2110-5 (2003) (Pubitemid 38030911)
81. H. Zaehres, M. W. Lensch, L. Daheron, S. A. Stewart, J. Itskovitz-Eldor and G. Q. Daley: High-efficiency RNA interference in human embryonic stem cells. Stem Cells, 23(3), 299-305 (2005) (Pubitemid 40404448)
82. S. A. Stewart, D. M. Dykxhoorn, D. Palliser, H. Mizuno, E. Y. Yu, D. S. An, D. M. Sabatini, I. S. Chen, W. C. Hahn, P. A. Sharp, R. A. Weinberg and C. D. Novina: Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA, 9(4), 493-501 (2003) (Pubitemid 36356735)
83. D. A. Rubinson, C. P. Dillon, A. V. Kwiatkowski, C. Sievers, L. Yang, J. Kopinja, D. L. Rooney, M. Zhang, M. M. Ihrig, M. T. McManus, F. B. Gertler, M. L. Scott and L. Van Parijs: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet, 33(3), 401-6 (2003) ng1117 [pii] (Pubitemid 36278858)
84. J. C. Burns, T. Friedmann, W. Driever, M. Burrascano and J. K. Yee: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A, 90(17), 8033-7 (1993) (Pubitemid 23260849)
85. S. Shankar, I. Siddiqui and R. K. Srivastava: Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem, 304(1-2), 273-85 (2007) (Pubitemid 47456876)
86. G. Kallifatidis, V. Rausch, B. Baumann, A. Apel, B. M. Beckermann, A. Groth, J. Mattern, Z. Li, A. Kolb, G. Moldenhauer, P. Altevogt, T. Wirth, J. Werner, P. Schemmer, M. W. Buchler, A. V. Salnikov and I. Herr: Sulforaphane targets pancreatic tumor-initiating cells by NF-{kappa}B-induced anti-apoptotic signaling. Gut, 58(7), 949-63 (2009)
87. L. A. Boyer, T. I. Lee, M. F. Cole, S. E. Johnstone, S. S. Levine, J. P. Zucker, M. G. Guenther, R. M. Kumar, H. L. Murray, R. G. Jenner, D. K. Gifford, D. A. Melton, R. Jaenisch and R. A. Young: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell, 122(6), 947-56 (2005) (Pubitemid 41345211)
88. T. Kuroda, M. Tada, H. Kubota, H. Kimura, S. Y. Hatano, H. Suemori, N. Nakatsuji and T. Tada: Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. Mol Cell Biol, 25(6), 2475-85 (2005) (Pubitemid 40354640)
89. D. J. Rodda, J. L. Chew, L. H. Lim, Y. H. Loh, B. Wang, H. H. Ng and P. Robson: Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem, 280(26), 24731-7 (2005) (Pubitemid 40934562)
90. K. Mitsui, Y. Tokuzawa, H. Itoh, K. Segawa, M. Murakami, K. Takahashi, M. Maruyama, M. Maeda and S. Yamanaka: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell, 113(5), 631-42 (2003) (Pubitemid 36694188)
91. I. Chambers, D. Colby, M. Robertson, J. Nichols, S. Lee, S. Tweedie and A. Smith: Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell, 113(5), 643-55 (2003) (Pubitemid 36694189)
92. C. E. Hoei-Hansen, J. E. Nielsen, K. Almstrup, S. B. Sonne, N. Graem, N. E. Skakkebaek, H. Leffers and E. Rajpert-De Meyts: Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clin Cancer Res, 10(24), 8521-30 (2004) (Pubitemid 40053419)
93. M. Y. Wong and G. N. Chiu: Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment. Anticancer Drugs, 21(4), 401-10 (2010)
94. U. Nothlings, S. P. Murphy, L. R. Wilkens, B. E. Henderson and L. N. Kolonel: Flavonols and pancreatic cancer risk: the multiethnic cohort study. Am J Epidemiol, 166(8), 924-31 (2007) (Pubitemid 47511689)
95. G. Bobe, S. J. Weinstein, D. Albanes, T. Hirvonen, J. Ashby, P. R. Taylor, J. Virtamo and R. Z. Stolzenberg-Solomon: Flavonoid intake and risk of pancreatic cancer in male smokers (Finland). Cancer Epidemiol Biomarkers Prev, 17(3), 553-62 (2008) (Pubitemid 351469204)
96. U. Nothlings, S. P. Murphy, L. R. Wilkens, H. Boeing, M. B. Schulze, H. B. Bueno-de-Mesquita, D. S. Michaud, A. Roddam, S. Rohrmann, A. Tjonneland, F. Clavel-Chapelon, A. Trichopoulou, S. Sieri, L. Rodriguez, W. Ye, M. Jenab and L. N. Kolonel: A food pattern that is predictive of flavonol intake and risk of pancreatic cancer. Am J Clin Nutr, 88(6), 1653-62 (2008)
97. M. Mouria, A. S. Gukovskaya, Y. Jung, P. Buechler, O. J. Hines, H. A. Reber and S. J. Pandol: Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer, 98(5), 761-9 (2002) (Pubitemid 34225629)
98. C. Manach, G. Williamson, C. Morand, A. Scalbert and C. Remesy: Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr, 81(1 Suppl), 230S-242S (2005)
99. K. Nemeth, G. W. Plumb, J. G. Berrin, N. Juge, R. Jacob, H. Y. Naim, G. Williamson, D. M. Swallow and P. A. Kroon: Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur J Nutr, 42(1), 29-42 (2003) (Pubitemid 36286303)
100. V. D. Bokkenheuser, C. H. Shackleton and J. Winter: Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans. Biochem J, 248(3), 953-6 (1987) (Pubitemid 18012735)
101. K. Murota and J. Terao: Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch Biochem Biophys, 417(1), 12-7 (2003) (Pubitemid 36960043)
102. A. J. Day, F. J. Canada, J. C. Diaz, P. A. Kroon, R. McLauchlan, C. B. Faulds, G. W. Plumb, M. R. Morgan and G. Williamson: Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett, 468(2-3), 166-70 (2000) (Pubitemid 30110789)
103. G. Williamson, D. Barron, K. Shimoi and J. Terao: In vitro biological properties of flavonoid conjugates found in vivo. Free Radic Res, 39(5), 457-69 (2005) (Pubitemid 40711878)
104. V. C. de Boer, A. A. Dihal, H. van der Woude, I. C. Arts, S. Wolffram, G. M. Alink, I. M. Rietjens, J. Keijer and P. C. Hollman: Tissue distribution of quercetin in rats and pigs. J Nutr, 135(7), 1718-25 (2005) (Pubitemid 40980724)
105. P. Ader, A. Wessmann and S. Wolffram: Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radic Biol Med, 28(7), 1056-67 (2000) (Pubitemid 30314704)
106. E. J. Oliveira, D. G. Watson and M. H. Grant: Metabolism of quercetin and kaempferol by rat hepatocytes and the identification of flavonoid glycosides in human plasma. Xenobiotica, 32(4), 279-87 (2002) (Pubitemid 34596864)
107. Y. Liu, Y. Dai, L. Xun and M. Hu: Enteric disposition and recycling of flavonoids and ginkgo flavonoids. J Altern Complement Med, 9(5), 631-40 (2003) (Pubitemid 37377383)
108. T. Walle, U. K. Walle and P. V. Halushka: Carbon dioxide is the major metabolite of quercetin in humans. J Nutr, 131(10), 2648-52 (2001) (Pubitemid 32947790)
109. P. C. Hollman and M. B. Katan: Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother, 51(8), 305-10 (1997) (Pubitemid 27423753)
110. T. Kitamura, J. Nakae, Y. Kitamura, Y. Kido, W. H. Biggs, 3rd, C. V. Wright, M. F. White, K. C. Arden and D. Accili: The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest, 110(12), 1839-47 (2002) (Pubitemid 36076491)
111. D. H. Castrillon, L. Miao, R. Kollipara, J. W. Horner and R. A. DePinho: Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science, 301(5630), 215-8 (2003) (Pubitemid 36858475)
112. J. Nakae, W. H. Biggs, 3rd, T. Kitamura, W. K. Cavenee, C. V. Wright, K. C. Arden and D. Accili: Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet, 32(2), 245-53 (2002)
113. M. C. Hu, D. F. Lee, W. Xia, L. S. Golfman, F. Ou-Yang, J. Y. Yang, Y. Zou, S. Bao, N. Hanada, H. Saso, R. Kobayashi and M. C. Hung: IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell, 117(2), 225-37 (2004) (Pubitemid 38496242)
114. T. Furuyama, K. Kitayama, Y. Shimoda, M. Ogawa, K. Sone, K. Yoshida-Araki, H. Hisatsune, S. Nishikawa, K. Nakayama, K. Ikeda, N. Motoyama and N. Mori: Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem, 279(33), 34741-9 (2004) (Pubitemid 39318105)
115. E. Dejana, A. Taddei and A. M. Randi: Foxs and Ets in the transcriptional regulation of endothelial cell differentiation and angiogenesis. Biochim Biophys Acta, 1775(2), 298-312 (2007) (Pubitemid 46899342)
116. S. Chlench, N. Mecha Disassa, M. Hohberg, C. Hoffmann, T. Pohlkamp, G. Beyer, M. Bongrazio, L. Da Silva-Azevedo, O. Baum, A. R. Pries and A. Zakrzewicz: Regulation of Foxo-1 and the angiopoietin-2/Tie2 system by shear stress. FEBS Lett, 581(4), 673-80 (2007) (Pubitemid 46217926)
117. M. Potente, C. Urbich, K. Sasaki, W. K. Hofmann, C. Heeschen, A. Aicher, R. Kollipara, R. A. DePinho, A. M. Zeiher and S. Dimmeler: Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest, 115(9), 2382-92 (2005) (Pubitemid 41266200)
118. S. Shankar, Q. Chen and R. K. Srivastava: Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J Mol Signal, 3, 7 (2008)
119. R. K. Srivastava, T. G. Unterman and S. Shankar: FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Mol Cell Biochem, 337(1-2), 201-12 (2010)